At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
bendamustine plus rituximabdrug
Likely dose
bendamustine plus rituximab 90mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
In Brief
A Phase 2 clinical trial evaluating bendamustine plus rituximab for Marginal Zone B-cell Lymphoma. Completed, enrolled 27 participants across 11 sites.
Detailed Summary
This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarginal Zone B-cell Lymphoma
CountriesSouth Korea
CollaboratorsGyeongsang National University Hospital, Korea Cancer Center Hospital, Seoul National University Boramae Hospital, Hallym University Medical Center, Inje University, Gangnam Severance Hospital, Chonbuk National University Hospital, Chungnam National University, The Catholic University of Korea, Wonju Severance Christian Hospital, Gachon University Gil Medical Center, Seoul National University Bundang Hospital
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedMay 2015
Primary CompletionOct 2019
TodayJul 2026
First PostedMay 5, 2015
Enrollment StartMay 1, 2015
Primary CompletionOct 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.2 years ago
Interventions
bendamustine plus rituximabdrug
Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle